Microbot Medical Inc. — FY2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020. The filing is an annual report, not a standalone fourth-quarter report. Microbot is a preclinical medical-device company developing robotic technologies for minimally invasive procedures; it reported no product revenue.
Financial performance and liquidity
| Metric (US$ millions, except per-share data) | 2020 | 2019 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | 3.396 | 3.048 |
| General and administrative expense | 5.693 | 4.192 |
| Operating loss | (9.089) | (7.240) |
| Net loss | (9.169) | (7.247) |
| Basic and diluted net loss per share | (1.29) | (1.70) |
| Operating cash used | (7.252) | (6.451) |
| Investing cash used | (2.768) | (2.453) |
| Financing cash flow | (3.375) | 36.770 |
- At year-end, cash and cash equivalents were $19.650 million, marketable securities were $4.998 million, and restricted cash was $0.084 million. Working capital was approximately $23.908 million.
- Total assets were $26.279 million and total liabilities were $1.971 million. The filing reports lease liabilities of $0.813 million; no material conventional borrowings are shown on the balance sheet.
- Management said cash was expected to fund operations for at least 24 months, but warned that an adverse outcome or settlement in the Empery/Hudson Bay litigation could reduce runway to less than 24 months. A financial-statement note separately says unrestricted cash was expected to fund operations for more than 12 months.
Changes versus 2019
- Net loss widened by approximately $1.922 million, as operating expenses increased and the prior-year $0.096 million capital gain did not recur.
- R&D expense rose $0.348 million, primarily from salaries, professional services, and patent expenses. G&A rose $1.501 million, reflecting higher salaries, government fees, share-based compensation, insurance, and investor relations, partly offset by lower professional-services and travel costs.
- Operating cash use increased by $0.801 million. Financing cash flow swung from $36.770 million provided in 2019, largely from equity issuance, to $3.375 million used in 2020 for repayment to investors following litigation.
- Year-end cash and cash equivalents declined from $28.771 million to $19.650 million, while marketable securities increased from $2.521 million to $4.998 million. Shares outstanding were 7,108,133 at December 31, 2020 versus 7,185,628 a year earlier.
Business, outlook, and principal risks
- Pipeline: The lead programs are the Self-Cleaning Shunt (SCS) for hydrocephalus and normal-pressure hydrocephalus, and LIBERTY, a remotely operated, fully disposable endovascular robotic system. TipCAT and CardioSert-related technologies are also in the portfolio. The company had 42 issued or allowed patents and 23 pending applications.
- Development evidence: LIBERTY’s 2020 feasibility animal study met its endpoints with no intraoperative adverse events. SCS preclinical results were mixed: certain laboratory studies reported reduced blockage, while a Wayne State follow-up study did not show statistically significant differences between groups; the company also described animal safety findings as supportive but noted uncertainty.
- Subsequent regulatory update: In January 2021, Microbot said FDA discussions could allow it to apply for an SCS Early Feasibility Study using existing preclinical data. It expected a first-in-human study to begin after IDE approval, estimated for the third quarter of 2022; FDA authorization was not assured. LIBERTY FDA pre-submission was planned as early as Q4 2021, with submission planned for Q4 2022.
- Outlook: Management expects continuing losses and increased R&D spending as development advances. The company had no established commercial manufacturing, sales, or distribution infrastructure and expects to rely on third parties and potentially partnerships. No revenue or profitability guidance was provided.
- Funding and dilution: Microbot may seek additional equity, debt, grants, or other financing, including under an existing shelf registration. Financing may dilute shareholders, impose debt restrictions, or require licensing rights; no committed external funding source was disclosed.
- Litigation contingency: Empery and Hudson Bay seek rescission and return of $6.75 million from the 2017 financing. The motion to dismiss was denied in February 2021; management could not assess the likelihood of loss. No provision was recorded at December 31, 2020 because management concluded a loss was not probable and not reasonably estimable. The company had previously repaid $3.375 million following a separate adverse outcome related to the same financing.
- Other risks: Regulatory pathway and clinical-data requirements remain uncertain; COVID-19 could delay studies or disrupt suppliers; the SCS and TipCAT Technion license milestones include beginning first-in-human trials by December 2021; CardioSert has a buy-back clause tied to commercialization deadlines, including a 2022 deadline. The company also faces Israeli operating, currency, IP, reimbursement, manufacturing, competition, and Nasdaq-listing risks.
- The independent auditor issued an unqualified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an attestation on internal controls.
Key facts investors should verify
- Current unrestricted liquidity, cash burn, and whether management’s stated runway assumptions remain valid.
- Status and financial implications of the $6.75 million Empery/Hudson Bay claim, including any settlement, judgment, or required financing.
- Whether FDA accepts the SCS EFS/IDE approach, the actual clinical timetable, and what additional evidence or costs may be required.
- LIBERTY’s progress toward FDA submissions, and whether animal-study results translate into clinical safety, effectiveness, and commercial viability.
- Compliance with Technion development milestones and the CardioSert commercialization deadlines, and any resulting license or technology-rights exposure.
- Potential dilution from future capital raises and outstanding equity awards, as well as the company’s ability to establish manufacturing, reimbursement, and commercial partnerships.